An amphiphilic silicon phthalocyanine photosensitizer coupled with RGD cyclic peptide and its preparation method and use
By synthesizing an amphiphilic silicon phthalocyanine photosensitive agent with RGD cyclic peptide as the targeting group, the complex and cost-effective production process of polypeptide modified phthalocyanine is solved, and the photodynamic treatment effect and good efficiency of targeting tumor cells is achieved. The water-solubleness of the company shows excellent clinical application prospects.
Patent Information
- Application Number
- CN202110992448.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-08-27
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-08-27
AI Technical Summary
The production process of existing polypeptide-modified phthalocyanine is complex and costly, and it is difficult to maintain the activity of photosensitive molecules and improve solubility while ensuring target fraction modification to meet clinical application needs.
By synthesizing an amphiphilic silicon phthalocyanine photosensitive agent with RGD cyclic peptide as the targeting group, the RGD cyclic peptide is used to form an amide bond connection with the axial modification ligand of the silicon phthalocyanine, a simplified synthetic route includes dichlorosilic phthalocyanine , coupling steps of axially modified silicon phthalocyanine and RGD cyclic peptides, using high boiling point organic solvents and aprotic polar solvents to ensure that the photosensitizer does not aggregate in water and has high fluorescence intensity.
The high cellular phototoxicity of tumor cells with high expression of integrin was achieved, the synthesis route was simplified, the water solubility and photodynamic treatment effect was improved, and good clinical application prospects were shown.
Smart Images

Figure CN115721712B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a preparation method of amphiphilic RGD cyclic peptide coupled silicon phthalocyanine and application thereof in tumor photodynamic therapy, belonging to the field of biomedicine. Background Art
[0002] Phthalocyanine is an aromatic heterocycle with four isoindole rings bridged by nitrogen atoms. As a second-generation photosensitizer, phthalocyanine has many advantages in photodynamic therapy, including a maximum absorption wavelength in the near-infrared band (λ max >670nm) and high extinction coefficient (ξ max >1×10 5 M -1 cm -1 ). In addition to their strong absorption in the phototherapy window, phthalocyanines show low or no absorption at 400–600 nm, where the intensity of sunlight is highest. Therefore, phthalocyanines have lower sunlight-induced skin photosensitization toxicity than porphyrin-type photosensitizers. In addition, the chemical structure of phthalocyanines can be easily modified by introducing central metals, as well as axial, peripheral, and non-peripheral substituents. These modifications can regulate the physical and chemical properties of phthalocyanines, including pharmacokinetic and biodistribution properties. However, the poor water solubility and easy aggregation of phthalocyanines limit their further clinical application.
[0003] RGD cyclic peptide is a v The ligand of β3-integrin (a transmembrane glycoprotein receptor heterodimer overexpressed on the surface of tumor blood vessels and various tumor cells), involving tumors including lung cancer, bone cancer and neuroblastoma. Although peptide-modified phthalocyanines often have better tumor specificity and stronger photodynamic therapy efficacy for tumors, the current limitations of using peptides to modify phthalocyanines are often that the modification process is complicated, requiring multiple steps of purification and separation, and the production cost is relatively high. And the choice of phthalocyanine-peptide linker is also a key issue. How to ensure the modification of the target molecule while not reducing the activity of the photosensitive molecule, and at the same time make the photosensitive molecule have sufficient solubility to meet the needs of clinical applications, is a very important issue that needs to be considered. Summary of the invention
[0004] The purpose of the present invention is to synthesize an amphiphilic silicon phthalocyanine photosensitizer with RGD polypeptide as a targeting group, the structure of which is shown in the following formula I:
[0005]
[0006] In formula I, R represents a group RGD cyclic peptide connected to the carboxyl group on the silicon phthalocyanine axially modified ligand through an amide bond formed by the free amino group (-NH2) on the RGD cyclic peptide, and n is an integer of 1 to 100.
[0007] RGD cyclic peptide refers to a cyclic polypeptide containing a sequence of three amino acids: arginine-glycine-aspartic acid. RGD cyclic peptides containing free amino groups include but are not limited to c(RGDfK), c(RGDyK), etc., where c(RGDfK) is cyclo(Arg-Gly-Asp-d-Phe-Lys) and c(RGDyK) is cyclo(Arg-Gly-Asp-d-Tyr-Lys).
[0008] The value range of n is preferably 1-4.
[0009] The amphiphilic silicon phthalocyanine photosensitizer shown in formula I can be used as a photosensitizing drug for photodynamic therapy of tumors or a diagnostic agent for photodynamic diagnosis.
[0010] The present invention also provides a method for synthesizing the amphiphilic silicon phthalocyanine photosensitizer shown in formula I, comprising the following steps:
[0011] 1) Synthesis of dichlorosilicon phthalocyanine: Dichlorosilicon phthalocyanine adopts the isoindole route, and isoindole and silicon tetrachloride are heated in a high boiling point organic solvent (such as quinoline) to obtain it through a condensation reaction;
[0012] 2) Synthesis of axially modified silicon phthalocyanine: dichlorosilicon phthalocyanine and the corresponding axial ligand (OH-Ph-(C2H4) n -COOH) as raw material, sodium hydride as catalyst, and reflux reaction in an organic solvent such as toluene;
[0013] 3) Synthesis of amphiphilic silicon phthalocyanine coupled with RGD cyclic peptide: The RGD cyclic peptide containing free amino group (-NH2) is subjected to amide reaction in an organic solvent at a molar ratio of 1:1 through the free amino group and the carboxyl group (-COOH) in the axially modified ligand of silicon phthalocyanine under anhydrous conditions to obtain amphiphilic silicon phthalocyanine coupled with RGD cyclic peptide.
[0014] The synthesis route of the amphiphilic silicon phthalocyanine photosensitizer of the present invention is as follows:
[0015]
[0016] The high boiling point organic solvent used in the above step 1) is, for example, quinoline or nitrobenzene, and has a boiling point above 200° C. at normal pressure. The reaction temperature in step 1) is preferably 170 to 200° C., and the reaction time is 1 to 2 h.
[0017] The organic solvent used in the above step 2) is preferably an aprotic solvent with a relatively high boiling point, such as toluene, tetrahydrofuran (THF), etc., with a boiling point above 100° C. under normal pressure, and is heated to reflux for reaction for 12 to 24 hours.
[0018] The organic solvent used in the above step 3) is preferably an aprotic polar solvent, such as N,N-dimethylformamide (DMF) and dimethyl sulfoxide (DMSO).
[0019] The experiment of the present invention proves that the amphiphilic silicon phthalocyanine photosensitizer does not aggregate in a physiological buffer solution containing 1% Cremophor EL (CEL), and its fluorescence intensity in physiological saline solution containing 1% CEL is higher than that in a polar solvent at the same concentration.
[0020] The amphiphilic silicon phthalocyanine photosensitizer coupled with RGD cyclic peptide of the present invention can target tumor cell lines with high expression of integrin, and its cell phototoxicity is stronger than that of non-targeted silicon phthalocyanine photosensitizer. Moreover, the photosensitizer has a simple synthesis route, good water solubility, does not aggregate in water, has a good photodynamic therapy effect on tumor cell lines with high expression of integrin, and shows good application prospects in the photodynamic therapy of tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The invention discloses a synthetic route of an amphiphilic silicon phthalocyanine photosensitizer wherein n=1 in formula I and the R group is cRGDyK.
[0022] Figure 2 This is a mass spectrometry characterization diagram of the amphiphilic silicon phthalocyanine photosensitizer prepared in Example 1 of the present invention.
[0023] Figure 3 This is the NMR characterization image of the amphiphilic silicon phthalocyanine photosensitizer prepared in Example 1 of the present invention.
[0024] Figure 4 The absorption spectrum (A) and fluorescence spectrum (B) of the amphiphilic silicon phthalocyanine photosensitizer prepared in Example 1 of the present invention in different solvents. DETAILED DESCRIPTION
[0025] The present invention will be further described below by way of embodiments in conjunction with the accompanying drawings, which will help to understand the content of the present invention but will not limit the scope of the present invention in any way.
[0026] Example 1
[0027] The amphiphilic silicon phthalocyanine photosensitizer prepared in this example, n=1, the R group is cRGDyK, and its preparation method is as follows:
[0028] (1) Synthesis of dichlorosilane phthalocyanine (Compound 1): 10 g of isoindole and 10 mL of silicon tetrachloride were added to a 500 mL three-necked flask, and they were dissolved in 200 mL of quinoline. After being fully stirred, the mixture was heated to 180°C and the reaction was stopped after 2 hours. After the solution was cooled to room temperature, it was poured into 400 mL of DMF to generate a dark green solution. The filter residue was repeatedly washed with chloroform, dichloromethane, methanol, acetone, tetrahydrofuran, and benzene until the filtrate was colorless, and a pure bright purple solid was obtained. After the solid was dried, 4.8 g of dichlorosilane phthalocyanine was obtained, with a yield of 11.2%.
[0029] (2) Synthesis of axial p-hydroxyphenylpropionic acid-modified silicon phthalocyanine (Compound 2): 100 mg of dichlorosilicon phthalocyanine, 108 mg of p-hydroxyphenylpropionic acid, and 16.4 mg of sodium hydride were added to a 100 mL round-bottom flask, dissolved in 15 mL of anhydrous toluene, and heated under reflux for 24 h. After the reaction was completed, the reaction solution was cooled to room temperature, the solvent was dried, the obtained solid was fully washed with water and filtered, the obtained filter residue was fully dissolved in DMF and filtered, the filtrate was dried and dried to obtain 57 mg of p-hydroxyphenylpropionic acid-modified silicon phthalocyanine (SC), with a yield of 39%.
[0030] (3) Synthesis of cRGD-modified targeted silicon phthalocyanine (Compound 3): 20 mg of SC obtained in the previous step, 4.4 mg of EDC (1-ethyl-(3-dimethylaminopropyl) carbodiimide), and 2.6 mg of NHS (N-hydroxysuccinimide) were dissolved in 2 mL of anhydrous DMF and stirred at room temperature for 4 h. Then, 4.27 mg of cRGDyK was added and the reaction solution was stirred at room temperature overnight. The reaction solution was poured into excess ether and filtered. After the filter residue was fully washed with dichloromethane, the filter residue was collected and fully washed with water. The resulting precipitate was vacuum dried to obtain 2.43 mg of cRGD-modified targeted silicon phthalocyanine (SR) with a yield of 24%.
[0031] 1H NMR (500MHz, DMSO) δ9.52 (ddd, J=8.4, 7.8, 4.3Hz, 8H), 8.37 (dt, J=7.9, 6.7Hz, 8H), 7.93 (s, 1H), 6.75 (dd, J=8.4, 3.0Hz, 2H), 6.4 2(dd,J=8.5,2.1Hz,2H),5.25(d,J=7.5Hz,3H),4.35(s,2H),4.05–3.93(m,2H),2.03(t,J=7.9Hz,4H),1.67(s,4H),1.33(s,4H).
[0032] Example 2
[0033] The absorption spectra of the amphiphilic silicon phthalocyanine photosensitizer (Compound 3) synthesized in Example 1 in different solvents (physiological saline containing 1% CEL, DMEM culture medium containing 0.05% CEL, and DMF) were tested using a UV-Vis-NIR spectrometer. The solvent used to dissolve silicon phthalocyanine was used as a blank, the scanning wavelength range was 200 to 900 nm, and the results were recorded and output.
[0034] The results are as follows Figure 4 As shown in Figure A, it can be seen that the amphiphilic silicon phthalocyanine photosensitizer synthesized in Example 1 exists in the form of monomers in both the physiological saline containing 1% CEL and the DMEM medium containing 0.05% CEL, and the absorption spectrum in DMF is almost completely overlapped, and the Q band absorption peak is sharp. The results of the absorption spectrum show that the amphiphilic silicon phthalocyanine photosensitizer synthesized in Example 1 has good solubility in both cell culture medium and physiological saline, and exists in the form of monomer molecules.
[0035] Example 3
[0036] The fluorescence spectrum properties of the amphiphilic silicon phthalocyanine photosensitizer (Compound 3) prepared in Example 1 were tested.
[0037] During the test, the excitation wavelength was 610 nm, the emission wavelength was 680-690 nm, the scanning range was 200-800 nm, the slit width was 5 nm, and the test temperature was 25°C.
[0038] The results are as follows Figure 4 As shown in Figure B, it can be seen that the fluorescence intensity of the amphiphilic silicon phthalocyanine photosensitizer synthesized in Example 1 in physiological saline is higher than that in the organic solvent DMF, while the fluorescence intensity in DMEM is similar to that in DMF. This shows that the amphiphilic silicon phthalocyanine photosensitizer has the characteristic of not aggregating in physiological saline and cell culture medium.
[0039] Although the best embodiment and the accompanying drawings of the present invention are disclosed for illustrative purposes, it will be understood by those skilled in the art that various substitutions, changes and modifications are possible without departing from the scope of the present invention and the appended claims, and the present invention should not be limited to the contents disclosed in the best embodiment and the accompanying drawings. Therefore, the protection scope of the present invention shall be subject to the appended claims.
Claims
1. A silicon phthalocyanine photosensitizer, which is an amphiphilic silicon phthalocyanine photosensitizer with RGD polypeptide as a targeting group, and its structure is shown in the following formula I: in, R represents a group that forms an amide bond with the carboxyl group on the axially modified silicon phthalocyanine ligand through the free amino group on the RGD cyclic peptide, and n is an integer of 1-100.
2. The silicon phthalocyanine photosensitizer according to claim 1, characterized in that The RGD cyclic peptide is c(RGDfK) or c(RGDyK).
3. The silicon phthalocyanine photosensitizer according to claim 1, characterized in that n is an integer of 1 to 4.
4. The method for preparing the silicon phthalocyanine photosensitizer according to claim 1, comprising the following steps: 1) heating isoindole and silicon tetrachloride in an organic solvent to obtain dichlorosilylphthalocyanine through a condensation reaction; 2) Using sodium hydride as a catalyst, dichlorosilane phthalocyanine and the corresponding axial ligand OH-Ph-(C2H4) n -COOH is refluxed in an organic solvent to synthesize the axially modified silicon phthalocyanine shown in formula II; 3) Under anhydrous conditions, the RGD cyclic peptide containing free amino groups and the axially modified silicon phthalocyanine shown in formula II are subjected to an amide reaction in an organic solvent at a molar ratio of 1:1 to obtain the amphiphilic silicon phthalocyanine coupled with the RGD cyclic peptide shown in formula I.
5. The preparation method according to claim 4, characterized in that: Step 1) The organic solvent used in the reaction is selected from quinoline and nitrobenzene.
6. The preparation method according to claim 4, characterized in that: The reaction temperature of step 1) is 170-200° C., and the reaction time is 1-2 hours.
7. The preparation method according to claim 4, characterized in that: Step 2) The organic solvent used in the reaction is selected from toluene and tetrahydrofuran.
8. The preparation method according to claim 4, characterized in that: The organic solvent used in step 3) is an aprotic polar solvent.
9. The preparation method according to claim 8, characterized in that: The organic solvent used in step 3) is selected from N,N-dimethylformamide and dimethyl sulfoxide.
10. Use of the silicon phthalocyanine photosensitizer according to any one of claims 1 to 3 in the preparation of photosensitizing drugs for photodynamic therapy of tumors or diagnostic reagents for photodynamic diagnosis.
Citation Information
Patent Citations
Axial ALA-modified silicon phthalocyanine and preparation method and application thereof
CN104844645A
Synthesis and application of RGD polypeptide coupled SiPc (silicon phthalocyanine) photosensitizer
CN107226839A
Phthalocyanine-RGD polypeptide-graphene oxide composite nano material and preparation method and application thereof
CN111166882A
Silicon phthalocyanine compound and composite, their preparation and application thereof
CN1861603A
Photodynamic therapy composition
US20210060170A1
